Identification Of Biomarkers Predictive Of Response To Bevacizumab In Patients With Glioblastoma Multiforme
Funder
National Health and Medical Research Council
Funding Amount
$32,628.00
Summary
Despite multimodality therapy, the median survival for patients diagnosed with high grade malignant brain tumours is only 12 months. Patient response to therapy is highly variable. Our aim is to develop a “genetic signature” that will predict response to bevacuzimab (an agent targeting blood vessel formation). Identifying patients who will respond to bevacuzimab will save many patients from a toxic and costly therapy, from which they will derive little benefit.